GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
60 hedge funds and large institutions have $44.4M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 31 increasing their positions, 8 reducing their positions, and 6 closing their positions.
288% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 8
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
5% more funds holding
Funds holding: 57 → 60 (+3)
48% less capital invested
Capital invested by funds: $86.2M → $44.4M (-$41.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.48M |
| 2 |
State Street
Boston,
Massachusetts
|
+$633K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$559K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$287K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$2.12M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.75M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$420K |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
-$237K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$82.4K |
GRNA Hedge Fund Activity: Q4 2022 in Review
60 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q4 2022, worth a combined $44.4M — down 48% from $86.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GRNA positions and 6 closed out — a net gain of 3 holders — while 31 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $2.48M. The largest seller was Baird Financial Group, cutting an estimated $2.12M.
- 60 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q4 2022, up from 57 in Q3 2022.
- Funds reported $44.4M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q4 2022, down 48% quarter-over-quarter.
- 9 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q4 2022 and 6 closed out, a net change of +3 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q4 2022 was BlackRock, an estimated $2.48M added.
- The largest GreenLight Biosciences Holdings, PBC Common Stock seller in Q4 2022 was Baird Financial Group, an estimated $2.12M sold.
Based on aggregated 13F filings for Q4 2022.